J
Jessica M. Frakes
Researcher at AMIT
Publications - 118
Citations - 1469
Jessica M. Frakes is an academic researcher from AMIT. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 17, co-authored 88 publications receiving 1006 citations.
Papers
More filters
Journal ArticleDOI
Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma.
Eric A. Mellon,Sarah E. Hoffe,Gregory M. Springett,Jessica M. Frakes,Tobin Strom,Pamela J. Hodul,Mokenge P. Malafa,Michael D. Chuong,Ravi Shridhar +8 more
TL;DR: The data underscore the feasibility, safety, and effectiveness of neoadjuvant SBRT and chemotherapy for BRPC and LAPC and show a trend for improved survival in those resected LapC patients.
Journal ArticleDOI
Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis
Quisette P. Janssen,Stefan Buettner,Mustafa Suker,Berend R. Beumer,Pietro Addeo,Philippe Bachellier,Nathan Bahary,Tanios Bekaii-Saab,Maria Antonietta Bali,Marc G. Besselink,Brian A. Boone,Ian Chau,Stephen Clarke,Mary Dillhoff,Bassel F. El-Rayes,Jessica M. Frakes,Derek Grose,Peter J. Hosein,Nigel B. Jamieson,Ammar A. Javed,Khurum Khan,Kyu Pyo Kim,Song Cheol Kim,Sunhee S. Kim,Andrew H. Ko,Jill Lacy,Georgios A. Margonis,Martin D. McCarter,Colin J. McKay,Eric A. Mellon,Sing Yu Moorcraft,Ken Ichi Okada,Alessandro Paniccia,Parag J. Parikh,Niek A. Peters,Hans Rabl,Jaswinder S. Samra,Christoph Tinchon,Geertjan van Tienhoven,Eran van Veldhuisen,Andrea Wang-Gillam,Matthew J. Weiss,Johanna W. Wilmink,Hiroki Yamaue,Marjolein Y.V. Homs,Casper H.J. van Eijck,Matthew H.G. Katz,Bas Groot Koerkamp +47 more
TL;DR: This patient-level meta-analysis of BRPC patients treated with neoadjuvant FOLFIRINOX showed a favorable median OS, resection rate, and R0-resection rate, which need to be assessed in a randomized trial.
Journal ArticleDOI
Radiosensitivity Differences Between Liver Metastases Based on Primary Histology Suggest Implications for Clinical Outcomes After Stereotactic Body Radiation Therapy
Kamran Ahmed,Jimmy J. Caudell,Ghassan El-Haddad,Anders Berglund,Eric A. Welsh,Binglin Yue,Sarah E. Hoffe,Arash O. Naghavi,Yazan Abuodeh,Jessica M. Frakes,Steven A. Eschrich,Javier F. Torres-Roca +11 more
TL;DR: It is suggested that primary histology may be an important factor to consider in SBRT radiation dose selection.
Journal ArticleDOI
Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy and neoadjuvant stereotactic body radiotherapy.
Eric A. Mellon,W. Jin,Jessica M. Frakes,Barbara A. Centeno,Tobin Strom,Gregory M. Springett,Mokenge P. Malafa,Ravi Shridhar,Pamela J. Hodul,Sarah E. Hoffe +9 more
TL;DR: Pre-operative PET-CT and CA19-9 response correlate with histopathologic tumor regression, suggesting a rationale for intensification and personalization of neoadjuvant therapy in BRPC and LAPC.
Journal ArticleDOI
Radiosensitivity index predicts for survival with adjuvant radiation in resectable pancreatic cancer.
Tobin Strom,Sarah E. Hoffe,William J. Fulp,Jessica M. Frakes,Domenico Coppola,Gregory M. Springett,Mokenge P. Malafa,Cynthia L. Harris,Steven A. Eschrich,Javier F. Torres-Roca,Ravi Shridhar +10 more
TL;DR: In this paper, the authors evaluated whether RSI is predictive of survival in pancreatic cancer treated with radiation and found that low-risk patients lived longer than both high risk patients with radiosensitive tumors and radioresistant tumors (HR 2.7 [1.0, 7.2], p = 0.04).